Harrow, Inc. · NASDAQ:HROW
Harrow — Imprimis Pharmaceuticals — Investor Presentation (August 2018)
22 slides from Harrow's investor presentation, Aug 8, 2018
Slide 1: Imprimis Pharmaceuticals August 2018
imprimis. PHARMACEUTICALS NASDAQ: IMMY AUGUST 2018
Slide 2: Safe Harbor
SAFE HARBOR This presentation contains express “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assump
Slide 3: IMPMMISR BARK Em Gurtace MELT
2014 2015 2017 2018 2018 w IMPMMISR BARK Em 3 Gurtace MELT COMPOUNDING 2017) filings + 238% revenue CAGR in ophthalmology (2014- + 153% consolidated revenue CAGR (2014-2017) * 60+ formulation and method of use patent + Balance sheet value in retained equity positions + Significant cash flow potentia
Slide 4: 100% Ownership Operating Businesses and Equity Interests
° e o%e ee@ee imprimi PHARMACEUTICALS 100% OWNERSHIP OPERATING BUSINESSES IMPFIMIS p elon ae @urtoce MELT COMPOUNDING ts
Slide 5: 100% Ownership Operating Businesses
100% OWNERSHIP OPERATING BUSINESSES wo) IMPFIMIs p- PARK COMPOUNDING
Slide 6: ImprimisRx and Park Compounding: What Is It?
IMPFIMIS p VY PARK COMPOUNDING WHAT IS IT? + ImprimisRx is the leading ophthalmology compounding businesses in U.S. + Serve ophthalmologists treating cataracts, LASIK, glaucoma, and dry eye| + 3,000+ physician customers (and growing) ordering ~20 SKUs + IP focused; 60+ patents filed + 2M+ sterile do
Slide 7: Consolidated Financial Performance
@ CONSOLIDATED FINANCIAL PERFORMANCE (IN THOUSANDS) Trends Revenue Growth: 2014-2017 + 238% CAGR (ophthalmic) + 153% CAGR (consolidated) Gross Margins: Continued expansion Profitability: Declining losses, turning to earnings $9,000 = Ophthalmology Sales (ImprimisRx) ™Non-Ophthalmology Sales (Park) Q
Slide 8: Ophthalmology Revenue Goal Roadmap
OPHTHALMOLOGY REVENUE GOAL ROADMAP Imprimis R OPPORTUNITY IN U.S. FY 2021: $100M RUN RATE} WHERE WE ARE @ OPHTHALMIC SURGERY Formulations include antibiotics, anti- inflammation, sedation, mydriatics, and anesthetics $1+ billion drug market ~4.6M ocular surgeries and other procedures'®. 810.1217 Dem
Slide 9: Equity & Royalty Interests
EQUITY & ROYALTY INTERESTS L
Slide 10: Eton Pharmaceuticals
elon pharmaceuticals WHAT IS IT? Focus on drug candidates requiring single small Plll trials, bio-equivalence, or literature-based 505(b)(2) NDA filings Seven active drug development programs: + One NDA filed; one ANDA filed + Additional NDA filings planned in 2019 Successful PIll data on allergic c
Slide 11: Surface Pharmaceuticals
Gurface PHARMACEUTICALS INC WHAT IS IT? + Focused on >$1B ocular surface disease and related markets « Imprimis contributed 505(b)(2) drug candidates have up to five indications: * Dry eye disease (chronic, episodic and refractory), pain and inflammation, post ocular surgery and blepharitis + Patent
Slide 12: Melt Pharmaceuticals
MELT Priaewaceurics:s Re WHAT IS IT? + Owns patented non-opioid conscious sedation / analgesia drug candidates + ~100 million U.S. procedures annually**’ where Melt formulations could replace and/or augment IV sedation + Multi-billion dollar market opportunity (ophthalmology, dental, MRI claustropho
Slide 13: Summary of Launched 505(b)(2) Drug Development Companies
SUMMARY OF LAUNCHED 505(B)(2) DRUG DEVELOPMENT COMPANIES COMPANY DRUG CANDIDATE MARKET OPPORTUNITY ROYALTY RATE Synthetic Corticotropin (39 peptide AA) Infantile Spasms, Rheumatoid Arthritis $1.1B+ (Acthar Gel® 17 sales'2) 6% G@urtace Mycophenolic Acid + Klarity Chronic Dry Eye Betamethasone + Kiari
Slide 14: Summary
Slide 15: Key Takeaways
KEY TAKEAWAYS Our operating business is profitable; it’s an innovation engine; and on plan to reach $100M in revenue in 2021 Growing balance sheet with equity positions in well funded and well managed 505(b)(2) pharmaceutical companies Significant income potential through royalty stakes in numerous
Slide 16: Company Profile
COMPANY PROFILE (as of August 1, 2018) TRADING SYMBOL: PRICE PER SHARE: STOCK PRICE RANGE (52-WEEkK): NASDAQ: IMMY $2.40 $1.35 - $4.69 AVG. DAILY Q2 TRADING VOLUME: SHARES OUTSTANDING: 84,000 SHARES 21.05 MILLION INSIDER BENEFICIAL OWNERSHIP: CORPORATE HEADQUARTERS: PRODUCTION FACILITIES: 13% SAN DI
Slide 17: References and Appendix
REFERENCES AND APPENDIX
Slide 18: References
@ REFERENCES Market Scope, LLC, Comprehensive Report on the Global IOL Market (2013, May) Allen, A. (2007). Vasectomy Risks and Benefits. Retrieved November 08, 2016, from http://www webmd,com/men/featuresivasectomy- risks-benefits US Market Report Suite for Gastrointestinal Endoscopic Devices 2017
Slide 19: References
@ REFERENCES 16. 17. 18 19. 20. Irwin, K. (2012, December 10). Prostate cancer now detectable using imaging-guided biopsy, UCLA study shows. Retrieved January 08, 2017, from http:/inewsroom.ucla.edu/releases/prostate-cancer-now-detectable-241575 Centers for Disease Control and Prevention - United St
Slide 20: Reducing complexity of the pharmaceutical value chain
imprimis We reduce the complexity of the pharmaceutical Value Chain, eliminating the need for: Insurance companies Pharmacy benefit managers (PBM) Wholesalers
Slide 21: Published Clinical Data
PUBLISHED CLINICAL DATA In a study of 483 eyes undergoing cataract surgery with concomitant trabecular microbypass stent insertion, there were no statistically significant differences in the safety profiles of a study group of 234 eyes receiving an intravitreal injection (pars plana) of 0.2mL of Dro
Slide 22: Contact details
ee ee. 12264-EL CAMINO REAL, SUITE 350 oe oe ‘SAN DIEGO;.CA 92130 Tr j ) rir \ WS (858) 704-4040 IR@IMPRIMISPHARMA.COM [= ; PgR iene WWW.IMPRIMISRX. CoM
Imprimis Pharmaceuticals — Investor Presentation (August 2018) on 6ix